For the treatment of adult patients with moderately to severely active CD
STELARA® OFFERS UNIQUELY DESIGNED DOSING IN CD1
Single IV induction dose administered over at least 1 hour
Body weight† of patient at the time of dosing | Dose | Number of 130 mg/26 mL (5 mg/mL) STELARA® vials |
55 kg or less | 260 mg | 2 |
more than 55 kg to 85 kg | 390 mg | 3 |
more than 85 kg | 520 mg | 4 |
90-mg dose every 8 weeks after induction dose
6 subQ maintenance doses during Year 1
For optimal outcome, STELARA® should be dosed and administered as described in the Prescribing Information.
- Please refer to the Dosage and Administration section of the Prescribing Information for complete information on how to prepare and administer STELARA®
- STELARA® is intended for use under the guidance and supervision of a physician with patients who will be closely monitored and have regular follow-up
- Patients may self-inject with STELARA® after physician approval and proper training
- Patients should be instructed to follow the direction provided in the Medication Guide
CD=Crohn's disease; IV=intravenous; subQ=subcutaneous; TNF=tumor necrosis factor.
*Weight-based induction dosage regimen: STELARA® 260 mg (weight ≤55 kg), STELARA® 390 mg (weight >55 kg to 85 kg), and STELARA® 520 mg (weight >85 kg).
†Approximately 2.2 pounds per kilogram.